CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 93 enrolled
Drug / intervention
Tipifarnib +1 moredrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Biopsy-proven relapsed or refractory lymphoma of designated types (aggressive [closed], indolent [closed], or uncommon/T-cell/Hodgkin disease)
  • ✓Measurable disease: at least one lesion with single diameter ≥2 cm OR tumor cells in blood ≥5×10^9/L
  • ✓ECOG performance status 0, 1, or 2
  • ✓Expected survival ≥3 months
Key exclusion· 8
  • ✕Pregnant or breastfeeding women
  • ✕Peripheral neuropathy ≥grade 3
  • ✕Active CNS lymphoma
  • ✕Other active malignancies

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00082888
NCT00082888Phase 2Completed
CompareCT.gov

Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma

National Cancer Institute (NCI)·interventional·Posted May 19, 2004·Updated Apr 13, 2020

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Tipifarnib for Anaplastic Large Cell Lymphoma and 12 related conditions. Completed, enrolled 93 participants across 2 sites.

Detailed Summary

This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 19, 2004
Enrollment StartMar 24, 2004
Primary CompletionMay 20, 2009
Study CompletionJul 5, 2017
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 22.1 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Tipifarnibdrug

Given PO